The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
As the healthcare sector seeks to regain momentum following earnings volatility, McKesson (MCK) shares have staged a short-term price recovery despite weaker quarterly performance. According to reports, the stock rose 2.5% in a single day and 4% over a week, prompting a dual-method valuation analysis; while a P/E ratio of 19.6x suggests the stock is undervalued compared to a fair estimate of 27.3x, a Discounted Cash Flow (DCF) model indicates the stock is trading far above its estimated future cash flow value.
Sign in to access this content
Sign InWhen compared to peers in the pharmaceutical distribution space, MCK shows mixed relative valuation, with Cardinal Health (CAH) trading at a forward P/E of approximately 15.2x per market data, making McKesson’s earnings-based valuation appear relatively premium. However, steady revenue growth in the distribution segment remains a supportive factor, as recent quarterly results demonstrated resilient operating margins despite cost pressures, justifying the technical rebound observed in the shares.
Investors should watch current price levels closely, as MCK closed at $775.66 (close June 05, 2026) after reaching a high of $781.27. Looking ahead at the economic calendar, upcoming US macroeconomic data may influence broader market sentiment, while support levels near $759.85 remain a critical zone to test the sustainability of this rebound, given the lack of direct healthcare sector catalysts in the next seven days.